CSF2 and Sepsis: In an early phase 2 precision medicine sepsis trial, subjects with sepsis and confirmed low mHLA-DR were randomized to placebo or a daily dose of granulocyte–macrophage colony-stimulating factor (GM-CSF) for 8 days.